|Bid||21.50 x 800|
|Ask||24.69 x 1100|
|Day's Range||23.06 - 24.85|
|52 Week Range||20.24 - 79.70|
|Beta (5Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 02, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.91|
Subscribe to Yahoo Finance Plus to view Fair Value for DNLI
Shareholders in Denali Therapeutics Inc. ( NASDAQ:DNLI ) may be thrilled to learn that the analysts have just delivered...
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.77% and 72.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2022, and provided business highlights. “Recent achievements highlight the broad potential of our BBB-crossing Transport Vehicle (TV) platform and the transition of